World Health Organization

View all		Pandemic influenza		Travel
GACVS meetings		Quality control
Needle safety		Special reports

Position Papers - GACVS Meetings

GACVS: 26th Meeting, June 6–7, 2012 The safety of thimerosal; the safety of aluminium adjuvants; the safety profile of influenza vaccines during pregnancy; and also reviewed 3 general issues for vaccine pharmacovigilance: safety of immunization during pregnancy and lactation; causality assessment for serious individual cases of adverse events following immunization (AEFI); and core variables for AEFI monitoring.

PDF

GACVS: 25th Meeting, December 7–8, 2011 The safety of influenza A(H1N1)pdm09 vaccines; rotavirus vaccines and intussusception; vaccine safety in pregnancy and lactation; global network for post-marketing surveillance and AEFI monitoring; and implementing the Global Vaccine Safety Blueprint

PDF

GACVS: 24th Meeting, June, 2011 The committee reviewed new data on the safety profile of meningococcal A conjugate vaccine, a new approach for assessing the causes of serious adverse events following immunization (AEFI), preparation of information sheets describing the safety profile of important vaccines, and the development of global strategies to enhance capacity to monitor and respond to vaccine safety issues in low-income and middle-income countries. 7/22/11

PDF

Rotavirus Vaccine and Intussusception: Report from an expert consultation July, 22 2011

PDF

Statement on Narcolepsy and Vaccination April 21, 2011

HTML

GACVS: 23rd Meeting, December 8-9, 2010 Rotavirus vaccine and intussusception; Safety of pandemic influenza A(H1N1) 2009 vaccines; Yellow fever vaccine and HIV infection; Meningitis A conjugate vaccine.

PDF

GACVS: 22nd Meeting, June 16-17, 2010 The committee reviewed the safety of pandemic A (H1N1) influenza vaccines, an apparent increase in febrile reactions following administration of a seasonal influenza vaccine in Australia, the finding of DNA from porcine circoviruses in rotavirus vaccines, the safety of live attenuated hepatitis A vaccines, the safety profile of a prequalified meningococcal A conjugate vaccine, and new data on yellow fever vaccine-related risks.

PDF

GACVS: 21st Meeting, December 3-4, 2009 The committee reviewed the safety of pandemic A (H1N1) influenza vaccines and the safety profile of a meningococcus A conjugate vaccine that will soon be deployed in sub-Saharan Africa. The committee also discussed the use of BCG vaccine in areas with a high prevalence of infection with HIV and reviewed progress with global monitoring of adverse events following immunization.

PDF

GACVS: 20th Meeting, June 17-18, 2009 The Committee reviewed the safety profile of a malaria vaccine entering phase III clinical development, updated the safety profiles of rotavirus and human paillomavirus (HPV) vaccines, discussed preparedness for novel influenza virus vaccines and completed a review of the safety of measles vaccines in persons infected with HIV.

PDF

GACVS: 19th Meeting, December 17-18, 2008 Issues discussed included: Safety profiles of rotavirus vaccines and human papillomavirus (HPV) vaccines, discussed several vaccine safety alerts in immunization programs supported by WHO, and reviewed the progress of its support programs.

PDF

GACVS Response: October 2008 Global Advisory Committee on Vaccine Safety: response to the paper (in press) by Y. Mikaeloff and colleagues in Neurology entitled "Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood"

HTML

GACVS: 18th Meeting, June 18-19, 2008 Issues discussed included: yellow fever vaccines; more studies and enhanced surveillance to better understand the relative risks and benefits of vaccination against yellow fever; and the alleged association between vaccination and progression of inherited mitochondrial diseases.

HTML  |  PDF

GACVS: 17th Meeting, December 12-13, 2007 Issues discussed included: Guillain-Barré Syndrome and vaccination; and hepatitis B vaccination and rheumatoid arthritis.

HTML  |  PDF

GACVS: 16th Meeting, June 12-13, 2007 Issues discussed included: statements on Menactra update, monitoring vaccine safety, safety of BCG, and safety of rotavirus vaccine.

HTML  |  PDF

GACVS: 15th Meeting, November 29-30, 2006 Issues discussed included: Monitoring vaccine safety; report of the WHO Expert Committee on Biological Standardization; safety of vaccine formulations; vaccinating adolescents and young adults: problems with coincidental pathologies and safety assessments; safety of mumps vaccine strains; safety of BCG vaccine in HIV-infected children; update on Menactra and Guillain-Barré syndrome; pandemic influenza vaccines; safety of Japanese encephalitis vaccination in India; safety of pneumococcal conjugate vaccine.

PDF

GACVS: 14th Meeting, June 6-7, 2006 Issues discussed included: Vaccine safety monitoring and the WHO Programme for International Drug Monitoring; post-marketing surveillance of rotavirus vaccines; safety of squalene; Immunogenic overload; safety of pandemic influenza vaccines; safety issues of varicella vaccines; modus operandi of the Committee and additional information.

PDF

GACVS: 13th Meeting, December 1-2, 2005 Issues discussed included: Statements on pandemic influenza vaccine, adjuvants, rotavirus vaccine, subacute sclerosing panencephalitis and measles vaccine, chronic fatigue syndrome and hepatitis B vaccine, conjugate meningococcal vaccine and Guillain-Barré Syndrome, and an update on the Vaccine Safety Net project.

PDF

GACVS: 12th Meeting, June 9-10, 2005 Issues discussed included: Statements on mouse brain-derived Japanese encephalitis vaccine, safety of SA 14-14-2 Japanese encephalitis vaccine, isoniazid resistance of bacilli Calmette-Guerin strains, international drug monitoring, thimerosal, safety of hexavalent vaccines, subacute sclerosing panencephalitis and measles vaccination, and national regulatory authorities planning workshops.

PDF

GACVS: 11th Meeting, December 2-3, 2004 Issues discussed included: Statements on the safety of adjuvants, thimerosal, residual cellular DNA in vaccines, transmissible spongiform encephalopathies, potential risk of vaccines produced in yeast, safety of hexavalent vaccines, and yellow fever vaccine.

PDF

GACVS: 10th Meeting, June 10-11, 2004 Issues discussed included: Statements on the safety of adjuvants, dengue vaccine safety, and effect of DTP vaccination on child survival.

PDF

GACVS: 9th Meeting, December 3-4, 2003 Issues discussed included: Statements on intranasal influenza virus vaccine, influenza vaccines and neurological complications, influenza vaccination of women during pregnancy, safety issues in the poliomyelitis eradication campaign, and more.

PDF

GACVS: 8th Meeting, June 11-12, 2003 Issues discussed included: Adverse events following mumps vaccination; safety of smallpox vaccines; safety of BCG vaccination in immunocompromised individuals; thimerosal.

PDF

GACVS: 7th Meeting, December 16-17, 2002 Issues discussed included: MMR and autism; oculorespiratory syndrome; hepatitis B vaccination and leukaemia.

PDF

GACVS: 6th Meeting, June 20-21, 2002 Issues discussed included: Safety of thimerosal-containing vaccines; Hepatitis B vaccine and leukaemia; hepatitis B vaccine and multiple sclerosis; aluminum-containing vaccines and macrophagic myofasciitis; Bell palsy following intranasal vaccination; potential adverse impact of routine vaccination on child survival.

PDF

GACVS:5th Meeting, March 23, 2001 Issues discussed included: Causality assessment of adverse events following immunization.

PDF

GACVS: 1st Meeting, September 14-15, 1999 Issues discussed included: About GAVCS; macrophagic myofasciitis and aluminum-containing vaccines.

PDF

This page was reviewed on July 30, 2012